Evaluation of Bcl2 gene expression in MCF-7 Human Breast Cancer Cells under treatment of Centaurea Behen extract and Cisplatin
Archives of Advances in Biosciences,
Vol. 9 No. 4 (2018),
23 December 2018
,
Page 11-16
https://doi.org/10.22037/jps.v9i4.22430
Abstract
Introduction: Breast cancer is among the most common malignancies of human around the world. Millions of cases of cancer worldwide occur annually, which, if detected in a timely manner, are easier to treat and can be conveniently controlled. In 2008, about 1,384,155 breast cancer cases were detected worldwide, with about 459,000 of them deceased.Method:MTT assay was performed to evaluate cell proliferation.The BCL2 gene is an inhibitor of apoptosis that prevents the release of cytochrome C from mitochondria and leads to inhibition of various apoptosis stimuli. Due to the importance of this gene in the apoptotic process, the level of BCL2 gene expression under treatment of Cisplatin and Centaurea Behen agents for 24 hours and 48 hours was evaluated in this research,using the Real time-PCR method. It is noteworthy that Cisplatin as a DNA binding agent may be effective in treating breast cancer;moreover, some studies have shown that Centaurea Behenplant has an antioxidant effect that can be a preventive factor in cancer.Results: The results obtained related to Cisplatin showed that IC50 for cells treated with Cisplatin for 24 hours was about 2.91 mg/ml while IC50 for cells treated with Cisplatin for 48 hours was about 1.77 mg/ml. Similarly, results obtained related to Centaurea Behenherbal extract showed that IC50 for cells treated with Centaurea Behen for 24 hours was about 9.64 mg/ml while IC50 for cells treated with Centaurea Behen for 48 hours was about 7.85 mg/ml.Results showed that the expression level of gene under treatment of the Cisplatinand Centaurea Behenhas decreased compared to the non-treatment state, so this expression reduction showed a significant difference between samples group and control group .
.
- BCL2 gene
- Apoptosis
- Cisplatin
- Persian herbal medicine
- Centaurea Behen herbal extract
- Anti-neoplastic agent
How to Cite
References
Nafissi N, Saghafinia M, Motamedi MHK, Akbari ME. A survey of breast cancer knowledge and attitude in Iranian women. Journal of cancer research and therapeutics. 2012; 8(1): 46.
Banegas MP, Bird Y, Moraros J, King S, Prapsiri S, Thompson B. Breast cancer knowledge, attitudes, and early detection practices in United States-Mexico border Latinas. Journal of Women's Health. 2012; 21(1): 101–7.
Youlden DR, Baade PD, Valery PC, Ward LJ, Green AC, Aitken JF. Childhood cancer mortality in Australia. Cancer epidemiology. 2012; 36(5): 476–80.
Druesne-Pecollo N, Touvier M, Barrandon E, et al. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast cancer research and treatment. 2012; 135(3): 647–54.
Hortobagyi GN, La Garza Salazar J de, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clinical breast cancer. 2005; 6(5): 391–401.
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer treatment reviews. 2012; 38(6): 698–707.
Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences. 2001; 98(19): 10869–74.
Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet. 2011; 378(9805): 1812–23.
Creighton CJ. The molecular profile of luminal B breast cancer. Biologics: targets & therapy. 2012; 6: 289.
Maleksabet A, Dehghani S, Amiri SR, Nazemiyeh H, Samadi N. Anti-proliferative effects of fenugreek extract on human breast cancer cells. Scientia Guaianae. 2014; 5(3): 50–7.
Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381): 1322–6.
Willemse P, Sleijfer DT, Mulder NH, Vries EG de. Cisplatin in breast cancer. British journal of cancer. 1993; 67(3): 638.
Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent Cisplatin. Journal of Biological Chemistry. 2000; 275(31): 23899–903.
Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of clinical oncology. 2010; 28(7): 1145.
Romano B, Pagano E, Montanaro V, Fortunato AL, Milic N, Borrelli F. Novel insights into the pharmacology of flavonoids. Phytotherapy research. 2013; 27(11): 1588–96.
Viola H, Wasowski C, Stein ML de, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta medica. 1995; 61(03): 213–6.
Rustaiyan A, Niknejad A, Aynehchi Y. Chemical constituents of Centaurea brugueriana. Planta medica. 1982; 44(03): 185–6
- Abstract Viewed: 1001 times
- PDF Downloaded: 786 times